logo
Avery Dennison Announces Second Quarter 2025 Results

Avery Dennison Announces Second Quarter 2025 Results

Business Wire22-07-2025
MENTOR, Ohio--(BUSINESS WIRE)--Avery Dennison Corporation (NYSE: AVY), a leading global materials science and digital identification solutions company, today announced preliminary, unaudited results for its second quarter ended June 28, 2025. Non-GAAP financial measures referenced in this release are reconciled from GAAP in the attached financial schedules. Unless otherwise indicated, comparisons are to the same period in the prior year.
'We delivered a solid second quarter, with earnings above expectations in a dynamic environment, reflecting the strength of our overall portfolio,' said Deon Stander, president and CEO.
'While trade policy changes led to lower sourcing demand for apparel and general retail categories in the quarter, growth in our high-value categories and productivity in the base business offset the impact from tariffs.
'The broader impact of trade policy changes is unclear. We are prepared for various scenarios and will continue to leverage our proven playbook to safeguard earnings, while driving key initiatives to deliver strong profitable growth over the cycle,' added Stander.
'Once again, I extend my gratitude to our agile, engaged, and talented team for their unwavering focus on excellence and dedication to addressing the current challenges at hand.'
Second Quarter 2025 Results by Segment
Materials Group
Reported sales increased 0.2% to $1.6 billion.
Sales down 1.0% on organic basis
High-value categories, including Intelligent Labels, up low single digits in total; base categories down low single digits
Label Materials down low single digits
Graphics and Reflectives up high single digits; Performance Tapes and Medical up low single digits
Reported operating margin of 16.1%
Adjusted operating margin (non-GAAP) of 15.6%, down 20 basis points
Adjusted EBITDA margin (non-GAAP) of 17.8%, down 10 basis points, as the benefits from productivity and higher volume/mix were offset by the net impact of pricing and raw material inputs costs.
Solutions Group
Reported sales decreased 2.6% to $670 million.
Sales down 0.8% on organic basis
Sales in high-value categories, including Intelligent Labels, up low single digits
High-value categories, excluding the estimated indirect impact of tariffs, up high single digits
Intelligent Labels comparable to prior year; Vestcom up approximately 10%; Embelex down high single digits
Sales in base categories down mid-single digits
Overall apparel categories down mid-single digits
Reported operating margin of 8.9%
Adjusted operating margin of 10.0%, down 10 basis points
Adjusted EBITDA margin of 17.1%, up 30 basis points, as benefits from productivity were partially offset by lower volume in apparel and growth investments.
Other
Balance Sheet and Capital Deployment
During the first half of 2025, the company returned $503 million in cash to shareholders through a combination of share repurchases and dividends. The company repurchased 2.0 million shares at an aggregate cost of $360 million in the first half of the year. Net of dilution from long-term incentive awards, the company's share count was down 2.8 million compared to the same time last year. In the second quarter, the company increased its quarterly dividend to $0.94 per share, representing an increase of approximately 7% over the previous dividend rate.
The company continues to deploy capital in a disciplined manner, executing its long-term capital allocation strategy. The company's balance sheet remains strong. Net debt to adjusted EBITDA (non-GAAP) was 2.3x at the end of the second quarter.
Income Taxes
The company's reported effective tax rate was 26.0% for the second quarter. The adjusted tax rate (non-GAAP) for the quarter was also 26.0%.
Cost Reduction Actions
In the first half of the year, the company realized approximately $30 million in pre-tax savings from restructuring, net of transition costs, and incurred approximately $13 million in pre-tax restructuring charges.
Guidance
In its supplemental presentation materials, 'Second Quarter 2025 Financial Review and Analysis,' the company provides a list of factors that it believes will contribute to its financial results. Based on the factors listed and other assumptions, the company expects third quarter 2025 reported earnings per share of $2.14 to $2.30.
Excluding an estimated ~$0.10 per share impact of restructuring charges and other items, the company expects third quarter 2025 adjusted earnings per share of $2.24 to $2.40.
For more details on the company's results, see the summary tables accompanying this news release, as well as the supplemental presentation materials, 'Second Quarter 2025 Financial Review and Analysis,' posted on the company's website at www.investors.averydennison.com, and furnished to the SEC on Form 8-K.
Throughout this release and the supplemental presentation materials, amounts on a per share basis reflect fully diluted shares outstanding.
About Avery Dennison
Avery Dennison Corporation (NYSE: AVY) is a global materials science and digital identification solutions company. We are Making Possible™ products and solutions that help advance the industries we serve, providing branding and information solutions that optimize labor and supply chain efficiency, reduce waste, advance sustainability, circularity and transparency, and better connect brands and consumers. We design and develop labeling and functional materials, radio-frequency identification (RFID) inlays and tags, software applications that connect the physical and digital, and offerings that enhance branded packaging and carry or display information that improves the customer experience. Serving industries worldwide — including home and personal care, apparel, general retail, e-commerce, logistics, food and grocery, pharmaceuticals and automotive — we employ approximately 35,000 employees in more than 50 countries. Our reported sales in 2024 were $8.8 billion. Learn more at www.averydennison.com.
'Safe Harbor' Statement under the Private Securities Litigation Reform Act of 1995
Certain statements contained in this document are "forward-looking statements" intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, and financial or other business targets, are subject to certain risks and uncertainties.
We believe that the most significant risk factors that could affect our financial performance in the near term include: (i) the impact on underlying demand for our products from global economic conditions, tariffs, geopolitical uncertainty, and changes in environmental standards, regulations and preferences; (ii) competitors' actions, including pricing, expansion in key markets, and product offerings; (iii) the cost and availability of raw materials; (iv) the degree to which higher costs can be offset with productivity measures and/or passed on to customers through price increases, without a significant loss of volume; (v) foreign currency fluctuations; and (vi) the execution and integration of acquisitions.
Actual results and trends may differ materially from historical or anticipated results depending on a variety of factors, including but not limited to, risks and uncertainties related to the following:
International Operations – worldwide economic, social, geopolitical and market conditions; changes in geopolitical conditions, including those related to trade relations and tariffs, China, the Russia-Ukraine war, the Israel-Hamas war and related hostilities in the Middle East; fluctuations in foreign currency exchange rates; and other risks associated with international operations, including in emerging markets
Our Business – fluctuations in demand affecting sales to customers; fluctuations in the cost and availability of raw materials and energy; changes in our markets due to competitive conditions, technological developments, laws and regulations, and customer preferences; environmental regulations and sustainability trends; the impact of competitive products and pricing; the execution and integration of acquisitions; selling prices; customer and supplier concentrations or consolidations; the financial condition of distributors; outsourced manufacturers; product and service quality claims; restructuring and other cost reduction actions; our ability to generate sustained productivity improvement and our ability to achieve and sustain targeted cost reductions; the timely development and market acceptance of new products, including sustainable or sustainably-sourced products; our investment in development activities and new production facilities; the collection of receivables from customers; and our sustainability and governance practices
Information Technology – disruptions in information technology systems; cybersecurity events or other security breaches; and successful installation of new or upgraded information technology systems
Income Taxes – fluctuations in tax rates; changes in tax laws and regulations, and uncertainties associated with interpretations of such laws and regulations; outcome of tax audits; and the realization of deferred tax assets
Human Capital – recruitment and retention of employees and collective labor arrangements
Our Indebtedness – our ability to obtain adequate financing arrangements and maintain access to capital; credit rating risks; fluctuations in interest rates; and compliance with our debt covenants
Ownership of Our Stock – potential significant variability of our stock price and amounts of future dividends and share repurchases
Legal and Regulatory Matters – protection and infringement of our intellectual property; the impact of legal and regulatory proceedings, including with respect to compliance and anti-corruption, environmental, health and safety, and trade compliance
Other Financial Matters – fluctuations in pension costs and goodwill impairment
For a more detailed discussion of these factors, see 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' in our 2024 Form 10-K, filed with the Securities and Exchange Commission on February 26, 2025, and subsequent quarterly reports on Form 10-Q.
The forward-looking statements included in this document are made only as of the date of this document, and we undertake no obligation to update these statements to reflect subsequent events or circumstances, other than as may be required by law.
Second Quarter Financial Summary - Preliminary, unaudited
(in millions, except % and per share amounts)
2Q 2Q % Sales Change vs. PY
Net sales, by segment:
Materials Group
$
1,550.2
$
1,546.8
0.2
%
(1.0
%)
(1.0
%)
Solutions Group
670.3
688.5
(2.6
%)
(0.8
%)
(0.8
%)
Total net sales
$
2,220.5
$
2,235.3
(0.7
%)
(1.0
%)
(1.0
%)
% of Sales
2Q 2Q
%
2Q
2Q
2025
2024
Change
2025
2024
Segment adjusted operating income and margins:
Materials Group
$
242.5
$
244.5
15.6
%
15.8
%
Solutions Group
67.0
69.8
10.0
%
10.1
%
Corporate expense
(22.8
)
(25.5
)
Adjusted operating income and margins (non-GAAP)
$
286.7
$
288.8
(0.7
%)
12.9
%
12.9
%
Segment adjusted EBITDA and margins:
Materials Group
$
275.5
$
277.3
17.8
%
17.9
%
Solutions Group
114.8
115.6
17.1
%
16.8
%
Corporate expense
(22.8
)
(25.5
)
Adjusted EBITDA and margins (non-GAAP)
$
367.5
$
367.4
---
16.6
%
16.4
%
Net income as reported
$
189.0
$
176.8
6.9
%
8.5
%
7.9
%
Adjusted net income (non-GAAP)
$
189.5
$
196.0
(3.3
%)
8.5
%
8.8
%
Net income per common share, assuming dilution as reported
$
2.41
$
2.18
10.6
%
Adjusted net income per common share, assuming dilution (non-GAAP)
$
2.42
$
2.42
---
Adjusted free cash flow (non-GAAP)
$
188.9
$
142.5
YTD Adjusted free cash flow (non-GAAP)
$
135.8
$
200.6
See accompanying schedules A-4 to A-8 for reconciliations of non-GAAP financial measures from GAAP.
Expand
A-1
AVERY DENNISON CORPORATION
(In millions, except per share amounts)
(UNAUDITED)
Three Months Ended Six Months Ended
Jun. 28, 2025 Jun. 29, 2024 Jun. 28, 2025 Jun. 29, 2024
Net sales
$
2,220.5
$
2,235.3
$
4,368.8
$
4,386.6
Cost of products sold
1,581.4
1,572.6
3,108.2
3,091.7
Gross profit
639.1
662.7
1,260.6
1,294.9
Marketing, general and administrative expense
352.4
373.9
699.4
739.1
Other expense (income), net
0.5
27.0
20.4
39.6
Interest expense
34.0
29.2
64.9
57.8
Other non-operating expense (income), net
(3.3
)
(5.8
)
(6.6
)
(14.4
)
Income before taxes
255.5
238.4
482.5
472.8
Provision for income taxes
66.5
61.6
127.2
123.6
Net income
$
189.0
$
176.8
$
355.3
$
349.2
Per share amounts:
Net income per common share, assuming dilution
$
2.41
$
2.18
$
4.50
$
4.31
Weighted average number of common shares outstanding, assuming dilution
78.3
81.0
78.9
81.0
Expand
A-2
AVERY DENNISON CORPORATION
PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS
(In millions)
(UNAUDITED)
ASSETS Jun. 28, 2025 Jun. 29, 2024
Current assets:
Cash and cash equivalents
$
215.9
$
208.8
Trade accounts receivable, net
1,626.5
1,528.6
Inventories
1,026.9
979.9
Other current assets
314.5
250.5
Total current assets
3,183.8
2,967.8
Property, plant and equipment, net
1,604.2
1,590.0
Goodwill and other intangibles resulting from business acquisitions, net
2,744.6
2,790.7
Deferred tax assets
131.6
113.0
Other assets
904.0
836.7
Total assets
$
8,568.2
$
8,298.2
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Short-term borrowings and current portion of long-term debt and finance leases
$
922.0
$
1,172.3
Accounts payable
1,307.5
1,313.4
Other current liabilities
832.6
814.5
Total current liabilities
3,062.1
3,300.2
Long-term debt and finance leases
2,628.2
2,046.5
Other long-term liabilities
676.3
664.4
Shareholders' equity:
Common stock
124.1
124.1
Capital in excess of par value
821.9
833.1
Retained earnings
5,399.3
4,922.2
Treasury stock at cost
(3,693.7
)
(3,154.6
)
Accumulated other comprehensive loss
(450.0
)
(437.7
)
Total shareholders' equity
2,201.6
2,287.1
Total liabilities and shareholders' equity
$
8,568.2
$
8,298.2
Expand
A-3
AVERY DENNISON CORPORATION
(In millions)
(UNAUDITED)
Six Months Ended
Jun. 28, 2025 Jun. 29, 2024
Operating Activities
Net income
$
355.3
$
349.2
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation
100.3
98.7
Amortization
58.4
57.2
Provision for credit losses and sales returns
25.3
28.2
Stock-based compensation
14.7
17.4
Deferred taxes and other non-cash taxes
(12.0
)
(3.8
)
Other non-cash expense and loss (income and gain), net
20.8
46.6
Changes in assets and liabilities and other adjustments
(370.3
)
(276.0
)
Net cash provided by operating activities
192.5
317.5
Investing Activities
Purchases of property, plant and equipment
(66.0
)
(96.3
)
Purchases of software and other deferred charges
(15.2
)
(12.9
)
Purchases of Argentine Blue Chip Swap securities
---
(34.2
)
Proceeds from sales of Argentine Blue Chip Swap securities
---
24.0
Proceeds from sales of property, plant and equipment
15.7
0.3
Proceeds from insurance and sales (purchases) of investments, net
8.8
2.2
Proceeds from settlement of net investment hedges
6.2
---
Payments for acquisitions, net of cash acquired, and venture investments
(10.7
)
(1.9
)
Net cash used in investing activities
(61.2
)
(118.8
)
Financing Activities
Net increase (decrease) in borrowings with maturities of three months or less
816.2
(2.2
)
Repayments of long-term debt and finance leases
(551.6
)
(3.5
)
Dividends paid
(142.9
)
(136.2
)
Share repurchases
(360.0
)
(40.7
)
Net (tax withholding) proceeds related to stock-based compensation
(12.6
)
(18.4
)
Payments for settlement of fair value hedges
(13.5
)
---
Other
15.9
(1.1
)
Net cash used in financing activities
(248.5
)
(202.1
)
Effect of foreign currency translation on cash balances
4.0
(2.8
)
Increase (decrease) in cash and cash equivalents
(113.2
)
(6.2
)
Cash and cash equivalents, beginning of year
329.1
215.0
Cash and cash equivalents, end of period
$
215.9
$
208.8
Expand
A-4
Expand
Reconciliation of Non-GAAP Financial Measures from GAAP
We report our financial results in conformity with accounting principles generally accepted in the United States of America, or GAAP, and also communicate with investors using certain non-GAAP financial measures. These non-GAAP financial measures are not in accordance with, nor are they a substitute for or superior to, the comparable GAAP financial measures. These non-GAAP financial measures are intended to supplement the presentation of our financial results prepared in accordance with GAAP. We use these non-GAAP financial measures internally to evaluate trends in our underlying performance, as well as to facilitate comparisons with the results of competitors for quarters and year-to-date periods, as applicable. Based on feedback from investors and financial analysts, we believe that the supplemental non-GAAP financial measures we provide are also useful to their assessments of our performance and operating trends, as well as liquidity. Reconciliations of our non-GAAP financial measures from the most directly comparable GAAP financial measures are provided in accordance with Regulations G and S-K.
Our non-GAAP financial measures exclude the impact of certain events, activities or strategic decisions. The accounting effects of these events, activities or decisions, which are included in the GAAP financial measures, may make it more difficult to assess our underlying performance in a single period. By excluding the accounting effects, positive or negative, of certain items (e.g., restructuring charges, outcomes of certain legal matters and settlements, certain effects of strategic transactions and related costs, losses from debt extinguishments, gains or losses from curtailment or settlement of pension obligations, gains or losses on sales of certain assets, gains or losses on venture and other investments, currency adjustments due to highly inflationary economies, and other items), we believe that we are providing meaningful supplemental information that facilitates an understanding of our core operating results and liquidity measures. While some of the items we exclude from GAAP financial measures recur, they tend to be disparate in amount, frequency or timing.
We use the non-GAAP financial measures described below in the accompanying news release.
Sales change ex. currency refers to the increase or decrease in net sales, excluding the estimated impact of foreign currency translation, and where applicable, the currency adjustments for transitional reporting of highly inflationary economies and the reclassification of sales between segments. Additionally, where applicable, sales change ex. currency is also adjusted for an extra week in our fiscal year and the calendar shift resulting from an extra week in the prior fiscal year. The estimated impact of foreign currency translation is calculated on a constant currency basis, with prior-period results translated at current period average exchange rates to exclude the effect of foreign currency fluctuations. Our 2025 fiscal year that began on December 29, 2024 will end on December 31,2025; fiscal years 2026 and beyond will be coincident with the calendar year beginning on January 1 and ending on December 31.
Organic sales change refers to sales change ex. currency, excluding the estimated impact of acquisitions and product line divestitures.
We believe that sales change ex. currency and organic sales change assist investors in evaluating the sales change from the ongoing activities of our businesses and enhance their ability to evaluate our results from period to period.
Adjusted operating income refers to net income adjusted for taxes; other expense (income), net; interest expense; other non-operating expense (income), net; and other items.
Adjusted EBITDA refers to adjusted operating income before depreciation and amortization.
Adjusted operating margin refers to adjusted operating income as a percentage of net sales.
Adjusted EBITDA margin refers to adjusted EBITDA as a percentage of net sales.
Adjusted tax rate refers to the projected full-year GAAP tax rate, adjusted to exclude certain unusual or infrequent events that are expected to significantly impact that rate, such as effects of certain discrete tax planning actions, impacts related to enactments of comprehensive tax law changes, and other items.
Adjusted net income refers to income before taxes, tax-effected at the adjusted tax rate, and adjusted for tax-effected restructuring charges, and other items.
Adjusted net income per common share, assuming dilution (adjusted EPS) refers to adjusted net income divided by the weighted average number of common shares outstanding, assuming dilution.
We believe that adjusted operating margin, adjusted EBITDA margin, adjusted net income, and adjusted EPS assist investors in understanding our core operating trends and comparing our results with those of our competitors.
Net debt to adjusted EBITDA ratio refers to total debt (including finance leases) less cash and cash equivalents, divided by adjusted EBITDA for the last twelve months. We believe that the net debt to adjusted EBITDA ratio assists investors in assessing our leverage position.
Adjusted free cash flow refers to cash flow provided by operating activities, less payments for property, plant and equipment, less payments for software and other deferred charges, plus proceeds from company-owned life insurance policies, plus proceeds from sales of property, plant and equipment, plus (minus) net proceeds from insurance and sales (purchases) of investments, less net cash used for Argentine Blue Chip Swap securities. Where applicable, adjusted free cash flow is also adjusted for certain acquisition-related transaction costs. We believe that adjusted free cash flow assists investors by showing the amount of cash we have available for debt reductions, dividends, share repurchases, and acquisitions.
A-5
(UNAUDITED)
Three Months Ended Six Months Ended
Jun. 28, 2025 Jun. 29, 2024 Jun. 28, 2025 Jun. 29, 2024
Reconciliation of non-GAAP operating and EBITDA margins from GAAP:
Net sales
$
2,220.5
$
2,235.3
$
4,368.8
$
4,386.6
Income before taxes
$
255.5
$
238.4
$
482.5
$
472.8
Income before taxes as a percentage of net sales
11.5
%
10.7
%
11.0
%
10.8
%
Adjustments:
Interest expense
$
34.0
$
29.2
$
64.9
$
57.8
Other non-operating expense (income), net
(3.3
)
(5.8
)
(6.6
)
(14.4
)
Operating income before interest expense, other non-operating expense (income) and taxes
$
286.2
$
261.8
$
540.8
$
516.2
Operating margins
12.9
%
11.7
%
12.4
%
11.8
%
As reported net income
$
189.0
$
176.8
$
355.3
$
349.2
Adjustments:
Restructuring charges, net of reversals:
Severance and related costs, net of reversals
7.9
6.3
12.6
11.2
Asset impairment and lease cancellation charges
0.1
0.9
0.3
2.0
(Gain) loss on venture and other investments
1.8
15.0
16.1
17.2
Losses from Argentine peso remeasurement and Blue Chip Swap transactions
1.8
4.1
2.5
15.4
(Gain) loss on sales of assets
(11.1
)
---
(11.1
)
---
Outcomes of legal matters and settlements, net
---
0.4
---
0.2
Transaction and related costs
---
0.3
---
0.3
Interest expense
34.0
29.2
64.9
57.8
Other non-operating expense (income), net (1)
(3.3
)
(5.8
)
(6.6
)
(14.4
)
Provision for income taxes
66.5
61.6
127.2
123.6
Adjusted operating income (non-GAAP)
$
286.7
$
288.8
$
561.2
$
562.5
Adjusted operating margins (non-GAAP)
12.9
%
12.9
%
12.8
%
12.8
%
Depreciation and amortization
$
80.8
$
78.6
$
158.7
$
155.9
Adjusted EBITDA (non-GAAP)
$
367.5
$
367.4
$
719.9
$
718.4
Adjusted EBITDA margins (non-GAAP)
16.6
%
16.4
%
16.5
%
16.4
%
Reconciliation of non-GAAP net income from GAAP:
As reported net income
$
189.0
$
176.8
$
355.3
$
349.2
Adjustments:
Restructuring charges and other items
0.5
27.0
20.4
46.3
Argentine interest income
---
(0.5
)
(0.1
)
(4.1
)
Tax effect on restructuring charges and other items, and impact of adjusted tax rate
---
(7.3
)
(3.5
)
(10.3
)
Adjusted net income (non-GAAP)
$
189.5
$
196.0
$
372.1
$
381.1
(1) Includes Argentine interest income of $.1 for the six months ended June 28, 2025, and $.5 and $4.1 for the three and six months ended June 29, 2024, respectively. Argentine interest income was not significant for the three months ended June 28, 2025.
Expand
A-5
(continued)
AVERY DENNISON CORPORATION
(In millions, except % and per share amounts)
(UNAUDITED)
Three Months Ended Six Months Ended
Jun. 29, 2024 Jun. 28, 2025 Jun. 29, 2024
Reconciliation of non-GAAP net income per common share from GAAP:
As reported net income per common share, assuming dilution
$
2.41
$
2.18
$
4.50
$
4.31
Adjustments per common share, net of tax:
Restructuring charges and other items
0.01
0.33
0.26
0.57
Argentine interest income
---
---
---
(0.05
)
Tax effect on restructuring charges and other items, and impact of adjusted tax rate
---
(0.09
)
(0.04
)
(0.13
)
Adjusted net income per common share, assuming dilution (non-GAAP)
$
2.42
$
2.42
$
4.72
$
4.70
Weighted average number of common shares outstanding, assuming dilution
78.3
81.0
78.9
81.0
Our adjusted tax rate was 26% for both the three and six months ended June 28, 2025 and June 29, 2024.
(UNAUDITED)
Three Months Ended Six Months Ended
Jun. 28, 2025 Jun. 29, 2024 Jun. 28, 2025 Jun. 29, 2024
Reconciliation of non-GAAP free cash flow from GAAP:
Net cash provided by operating activities (1)
$
208.8
$
197.7
$
192.5
$
317.5
Purchases of property, plant and equipment
(30.0
)
(47.5
)
(66.0
)
(96.3
)
Purchases of software and other deferred charges
(7.6
)
(6.0
)
(15.2
)
(12.9
)
Purchases of Argentine Blue Chip Swap securities
---
(14.0
)
---
(34.2
)
Proceeds from sales of Argentine Blue Chip Swap securities
---
10.0
---
24.0
Proceeds from sales of property, plant and equipment
15.7
0.2
15.7
0.3
Proceeds from insurance and sales (purchases) of investments, net
2.0
2.1
8.8
2.2
Adjusted free cash flow (non-GAAP)
$
188.9
$
142.5
$
135.8
$
200.6
(1) Net cash provided by operating activities for the three and six months ended June 29, 2024 included payments associated with the settlement of a significant legal matter, net of taxes. The full-year 2024 cash payment, net of cash tax benefit, related to this settlement was $56.6.
Expand
A-6
AVERY DENNISON CORPORATION
(In millions, except %)
(UNAUDITED)
NET SALES
Three Months Ended Six Months Ended
Jun. 28, 2025 Jun. 29, 2024 Jun. 28, 2025 Jun. 29, 2024
Materials Group
$
1,550.2
$
1,546.8
$
3,030.3
$
3,043.3
Solutions Group
670.3
688.5
1,338.5
1,343.3
Total net sales
$
2,220.5
$
2,235.3
$
4,368.8
$
4,386.6
RECONCILIATION OF NON-GAAP SUPPLEMENTARY INFORMATION FROM GAAP
Three Months Ended Six Months Ended
Jun. 28, 2025 Jun. 29, 2024 Jun. 28, 2025 Jun. 29, 2024
Materials Group
Operating income, as reported
$
249.5
$
223.4
$
475.4
$
449.5
Adjustments:
Restructuring charges, net of reversals:
Severance and related costs, net of reversals
2.5
1.6
5.0
4.0
Asset impairment and lease cancellation charges
---
---
---
0.1
Losses from Argentine peso remeasurement and Blue Chip Swap transactions
1.8
4.1
2.5
15.4
(Gain) loss on venture and other investments
(0.2
)
15.0
1.0
15.0
(Gain) loss on sales of assets
(11.1
)
---
(11.1
)
---
Outcomes of legal matters and settlements, net
---
0.4
---
1.0
Adjusted operating income (non-GAAP)
$
242.5
$
244.5
$
472.8
$
485.0
Depreciation and amortization
33.0
32.8
64.5
65.6
Adjusted EBITDA (non-GAAP)
$
275.5
$
277.3
$
537.3
$
550.6
Operating margins, as reported
16.1
%
14.4
%
15.7
%
14.8
%
Adjusted operating margins (non-GAAP)
15.6
%
15.8
%
15.6
%
15.9
%
Adjusted EBITDA margins (non-GAAP)
17.8
%
17.9
%
17.7
%
18.1
%
Solutions Group
Operating income, as reported
$
59.8
$
64.1
$
117.9
$
120.2
Adjustments:
Restructuring charges, net of reversals:
Severance and related costs, net of reversals
5.1
4.5
6.9
6.9
Asset impairment and lease cancellation charges
0.1
0.9
0.3
1.9
(Gain) loss on venture and other investments
2.0
---
10.1
2.2
Transaction and related costs
---
0.3
---
0.3
Outcomes of legal matters and settlements, net
---
---
---
(0.8
)
Adjusted operating income (non-GAAP)
$
67.0
$
69.8
$
135.2
$
130.7
Depreciation and amortization
47.8
45.8
94.2
90.3
Adjusted EBITDA (non-GAAP)
$
114.8
$
115.6
$
229.4
$
221.0
Operating margins, as reported
8.9
%
9.3
%
8.8
%
8.9
%
Adjusted operating margins (non-GAAP)
10.0
%
10.1
%
10.1
%
9.7
%
Adjusted EBITDA margins (non-GAAP)
17.1
%
16.8
%
17.1
%
16.5
%
Expand
A-7
AVERY DENNISON CORPORATION
PRELIMINARY SUPPLEMENTARY INFORMATION
(In millions, except ratios)
(UNAUDITED)
QTD
3Q24
4Q24
1Q25
2Q25
Reconciliation of non-GAAP EBITDA from GAAP:
As reported net income
$
181.7
$
174.0
$
166.3
$
189.0
Other expense (income), net
15.3
16.7
19.9
0.5
Interest expense
30.0
29.2
30.9
34.0
Other non-operating expense (income), net
(4.9
)
(7.4
)
(3.3
)
(3.3
)
Provision for income taxes
57.6
67.4
60.7
66.5
Depreciation and amortization
78.1
78.2
77.9
80.8
Adjusted EBITDA (non-GAAP)
$
357.8
$
358.1
$
352.4
$
367.5
Total Debt
$
3,550.2
Less: Cash and cash equivalents
215.9
Net Debt
$
3,334.3
Net Debt to Adjusted EBITDA LTM* (non-GAAP)
2.3
*LTM = Last twelve months (3Q24 to 2Q25)
Expand
A-8
AVERY DENNISON CORPORATION
PRELIMINARY SUPPLEMENTARY INFORMATION
(UNAUDITED)
Second Quarter 2025
Total
Company Materials
Group Solutions
Group
Reconciliation of non-GAAP organic sales change from GAAP:
Reported net sales change
(0.7
%)
0.2
%
(2.6
%)
Reclassification of sales between segments
---
(0.8
%)
1.7
%
Foreign currency translation
(0.3
%)
(0.5
%)
0.2
%
Sales change ex. currency (non-GAAP) (1)
(1.0
%)
(1.0
%)
(0.8
%)
Organic sales change (non-GAAP) (1)
(1.0
%)
(1.0
%)
(0.8
%)
(1) Totals may not sum due to rounding.
Six Months Ended 2025
Total
Company Materials
Group Solutions
Group
Reconciliation of non-GAAP organic sales change from GAAP:
Reported net sales change
(0.4
%)
(0.4
%)
(0.4
%)
Reclassification of sales between segments
---
(0.7
%)
1.7
%
Foreign currency translation
1.0
%
1.2
%
0.7
%
Sales change ex. currency (non-GAAP) (1)
0.6
%
---
2.0
%
Organic sales change (non-GAAP) (1)
0.6
%
---
2.0
%
(1) Totals may not sum due to rounding.
Expand
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Genentech's Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)
Genentech's Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)

Business Wire

time13 minutes ago

  • Business Wire

Genentech's Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, five-year efficacy, safety and durability data from the Phase III Portal study, a long-term extension of the Phase III Archway study, of Susvimo ® (ranibizumab injection) for the treatment of people with wet AMD. Results show that Susvimo's immediate and predictable durability was sustained over five years, with approximately 95% of people receiving treatment every six months requiring no supplemental treatment before each refill. The data were presented at the American Society of Retina Specialists (ASRS) 2025 Annual Meeting in Long Beach, California. 'These long-term results reinforce Susvimo's ability to maintain vision and retinal drying over a long period of time for people with wet AMD, the leading cause of vision loss in people over age 60,' said Levi Garraway, M.D., Ph.D., Genentech's chief medical officer and head of Global Product Development. 'These robust data reinforce our confidence in Susvimo's unique therapeutic approach, providing an effective alternative to regular eye injections while preserving vision in a sustained manner.' 'People with wet AMD often experience suboptimal outcomes with real-world anti-VEGF treatment, largely due to the frequency of injections,' said study investigator John Kitchens, M.D., Retina Associates of Kentucky, who presented the data at ASRS. 'Continuous delivery of treatment with Susvimo may preserve vision in patients with wet AMD for longer in real-world clinical use than IVT injections.' In the Portal study (n = 352), people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort; n = 220), while those originally treated with monthly intravitreal (IVT) ranibizumab injections in Archway received Susvimo and then refills every six months (IVT-Susvimo cohort; n = 132). Five-year results showed consistent and sustained disease control and retinal drying in a population who entered Archway with vision at or near peak levels after receiving an average of five intravitreal injections per standard of care. In the Susvimo cohort, best-corrected visual acuity (BCVA) was 74.4 letters at baseline and 67.6 letters at 5 years. In the IVT-Susvimo cohort, BCVA was 76.3 letters at baseline and 68.6 at 5 years. Half of all patients had better than 20/40 vision at five years (Snellen visual acuity test). Average central subfield thickness (CST) remained stable, with a 1.0 (95% CI: -13.1, 11.1) µm reduction from baseline in the Susvimo cohort, and a 10.3 (95% CI: -25.7, 5.0) µm reduction in the IVT-Susvimo cohort. The cohort of people who entered the Portal study from Archway is the largest cohort of people with wet AMD to be followed prospectively and continuously for five years in a clinical study. Susvimo provides continuous delivery of a customized formulation of ranibizumab via the Port Delivery Platform, while other currently approved treatments may require eye injections as often as once per month. The Port Delivery Platform is a refillable eye implant surgically inserted into the eye during a one-time, outpatient procedure, which introduces medicine directly into the eye, addressing certain retinal conditions that can cause vision loss. About the Archway study and its open-label extension study (Portal) Archway (NCT03677934) was a randomized, multicenter, open-label Phase III study evaluating the efficacy and safety of Susvimo refilled every six months at fixed intervals, compared to monthly IVT ranibizumab 0.5 mg in 415 people living with wet AMD. Patients were randomized 3:2 to Susvimo (n = 248) or intravitreal (IVT) ranibizumab injections (n = 167). Patients enrolled in Archway were responders to prior treatment with anti-VEGF therapy. In both study arms, patients were treated with at least three anti-VEGF injections within the six months prior to their Archway screening visit, with an average of five anti-VEGF injections before randomization. The primary endpoint of the study was the change in BCVA score from baseline at the average of Week 36 and Week 40. Secondary endpoints include safety, overall change in vision (BCVA) from baseline and change from baseline in center point thickness over time. Patients who completed the study at week 96 were eligible to enter the Portal open-label extension study. In Portal, people originally treated with Susvimo in Archway continued to receive Susvimo refills every six months (Susvimo cohort), while those originally treated with monthly IVT ranibizumab injections in Archway received the Susvimo implant and then refills every six months (IVT-Susvimo cohort). Portal is ongoing. About Wet Age-Related Macular Degeneration (AMD) Age-related macular degeneration (AMD) is a condition that affects the macula, the part of the eye that provides sharp, central vision needed for activities like reading. It is a leading cause of blindness for people aged 60 and over in the U.S. Wet, or neovascular, AMD is an advanced form of the disease that can cause rapid and severe vision loss. Approximately 20 million people in the U.S. have some form of AMD, and of those, about 1.5 million have late-stage AMD, which includes wet AMD. Wet AMD is caused by growth of abnormal blood vessels, also referred to as choroidal neovascularization (CNV), into the macula. These vessels leak fluid and blood and cause scar tissue that destroys the central retina. This process results in a deterioration of sight over a period of months to years. Genentech is committed to helping people access the medicines they are prescribed and offers comprehensive services for people prescribed Susvimo to help minimize barriers to access and reimbursement. Patients can call 833-EYE-GENE for more information. For people who qualify, Genentech offers patient assistance programs through Genentech Access Solutions. More information is also available at (866) 4ACCESS/(866) 422-2377 or Visit for additional information. Susvimo ® (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure. Susvimo continuously delivers a customized formulation of ranibizumab over time. Susvimo is indicated for intravitreal use via the Susvimo eye implant only. Ranibizumab is a vascular endothelial growth factor (VEGF) inhibitor designed to bind to and inhibit VEGF-A, a protein that has been shown to play a critical role in the formation of new blood vessels and the leakiness of the vessels. Susvimo was previously called the Port Delivery System with ranibizumab in the U.S. The customized formulation of ranibizumab delivered by Susvimo is different from the ranibizumab intravitreal injection, a medicine marketed as Lucentis ® (ranibizumab injection), which is approved to treat wet, or neovascular, age-related macular degeneration (AMD) and other retinal diseases. Lucentis was first approved for wet AMD by the FDA in 2006. Susvimo Indication Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR) who have previously responded to at least two intravitreal injections of a vascular endothelial growth factor inhibitor medication. Susvimo Important Safety Information WARNING: ENDOPHTHALMITIS The Susvimo implant has been associated with an up to 3-fold higher rate of endophthalmitis than monthly intravitreal injections of ranibizumab. Warnings and Precautions: The Susvimo implant and the procedures associated with inserting, filling, refilling, and (if medically necessary) removing the implant can cause other serious side effects, including: An eye infection (endophthalmitis). Endophthalmitis is an infection of the eyeball that can cause permanent damage to your eye, including blindness. Endophthalmitis requires urgent (same-day) medical or surgical treatment. A missing layer on top of the white part of the eye (conjunctival erosion). Conjunctival erosion is an area that becomes missing (defect) in the layer (conjunctiva) that covers the white part of the eye, which may result in exposure of the implant. Conjunctival erosion may require surgical treatment. An opening of the layer that covers the white part of the eye (conjunctival retraction). Conjunctival retraction is an opening or gaping in the layer (conjunctiva) that covers the white part of the eye, which may cause the implant to be exposed. Conjunctival retraction may require surgical treatment. Tear and separation of layers of the retina (rhegmatogenous retinal detachment). Rhegmatogenous retinal detachment is a tear and separation of one of the layers of the retina in the back of the eye that senses light. Rhegmatogenous retinal detachment requires surgical treatment. Implant movement (implant dislocation): This movement may require surgical treatment to correct. Implant damage: Damage to the implant that prevents continued treatment (refills) with Susvimo. If the implant is not able to be properly refilled, a patient's wet AMD may be inadequately treated and a physician may remove the implant and/or change the treatment. Bleeding (vitreous hemorrhage): Vitreous hemorrhage is bleeding within the gel-like substance (vitreous) inside of your eye. This may require an additional eye surgery. Bump on top of the white layer of the eye (conjunctival bleb): Conjunctival bleb is a small bulge in the layer (conjunctiva) that covers the white part of the eye where the implant is inserted. This may be due to leakage of fluid from the inside of the eye. This may require medical or surgical treatment. Temporary decrease in vision after the Susvimo procedure. Who should not receive Susvimo? Patients who have an infection in or around their eye, have active inflammation in their eye, or have had an allergic reaction to ranibizumab or any of its ingredients in Susvimo in the past. Information for patients who are of childbearing potential If patients are pregnant, think that they might be pregnant, or plan to become pregnant. It is not known if Susvimo will harm an unborn baby. Patients should use birth control (contraception) during treatment with Susvimo and for 12 months after the last refill of Susvimo. If patients are breastfeeding or plan to breastfeed. Susvimo is not recommended during breastfeeding. It is not known if Susvimo passes into breast milk. Adverse Reactions The most common adverse reactions were blood on the white of the eye, redness in the white of the eye, sensitivity to light, and eye pain. These are not all the possible side effects of Susvimo. You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Genentech at (888) 835-2555. Please see additional Important Safety Information in the full Susvimo Prescribing Information, including BOXED WARNING or visit About Lucentis ® (ranibizumab injection) Lucentis ® is a vascular endothelial growth factor (VEGF) inhibitor designed to bind to and inhibit VEGF-A, a protein that is believed to play a critical role in the formation of new blood vessels (angiogenesis) and the hyperpermeability (leakiness) of the vessels. Lucentis is FDA-approved for the treatment of patients with wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) and myopic choroidal neovascularization (mCNV). Lucentis was developed by Genentech, a member of the Roche Group. The company retains commercial rights in the United States and Novartis has exclusive commercial rights for the rest of the world. Outside the United States, Lucentis is approved in more than 120 countries to treat adult patients with wet AMD, and for the treatment of visual impairment due to DME, due to macular edema secondary to both branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO), and due to choroidal neovascularization (CNV). Lucentis Important Safety Information Lucentis is contraindicated in patients with ocular or periocular infections or known hypersensitivity to ranibizumab or any of the excipients in Lucentis. Hypersensitivity reactions may manifest as severe intraocular inflammation. Intravitreal injections, including those with Lucentis, have been associated with endophthalmitis, retinal detachment, and iatrogenic traumatic cataract. Increases in intraocular pressure have been noted both pre-injection and post-injection with Lucentis. Although there was a low rate of arterial thromboembolic events (ATEs) observed in the Lucentis clinical trials, there is a potential risk of ATEs following intravitreal use of VEGF inhibitors. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause). Fatal events occurred more frequently in patients with DME and DR at baseline treated monthly with Lucentis compared with control. Although the rate of fatal events was low and included causes of death typical of patients with advanced diabetic complications, a potential relationship between these events and intravitreal use of VEGF inhibitors cannot be excluded. Retinal vasculitis and/or retinal vascular occlusion have been reported. Patients should be instructed to report any change in vision without delay. In the Lucentis Phase III clinical trials, the most common ocular side effects included conjunctival hemorrhage, eye pain, vitreous floaters, and increased intraocular pressure. The most common non-ocular side effects included nasopharyngitis, anemia, nausea, and cough. You may report side effects to the FDA at (800) FDA-1088 or You may also report side effects to Genentech at (888) 835-2555. For additional safety information, please see Lucentis full Prescribing Information, available here: About Genentech in Ophthalmology Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), geographic atrophy (GA) and other retinal diseases, including rare and inherited conditions. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit

Udemy to Present at the Canaccord Genuity 45th Annual Growth Conference
Udemy to Present at the Canaccord Genuity 45th Annual Growth Conference

Business Wire

time13 minutes ago

  • Business Wire

Udemy to Present at the Canaccord Genuity 45th Annual Growth Conference

SAN FRANCISCO--(BUSINESS WIRE)-- Udemy (Nasdaq: UDMY), a leading AI-powered skills acceleration platform, today announced that Chief Executive Officer Hugo Sarrazin will participate in a fireside chat session during the Canaccord Genuity 45th Annual Growth Conference. On Tuesday, August 12, 2025 at 9:00 a.m. ET, a live webcast of the fireside chat discussion will be available through the ' Events & Presentations ' section of Udemy's investor relations website at An archived replay of the webcast will be available for approximately 90 days following the event. About Udemy Udemy (Nasdaq: UDMY) is an AI-powered skills acceleration platform transforming how companies and individuals across the world build the capabilities needed to thrive in a rapidly evolving workplace. By combining on-demand, multi-language content with real-time innovation, Udemy delivers personalized experiences that empower organizations to scale workforce development and help individuals build the technical, business, and soft skills most relevant to their careers. Today, thousands of companies, including Ericsson, Samsung SDS America, On24, Tata Consultancy Services, The World Bank, and Volkswagen, rely on Udemy Business for its enterprise solutions to build agile, future-ready teams. Udemy is headquartered in San Francisco, with hubs across the United States, Australia, India, Ireland, Mexico and Türkiye.

Centene Corporation (CNC) Faces Shareholder Ire Amidst Plummeting Stock and Lawsuit Over 'Inflated Guidance'
Centene Corporation (CNC) Faces Shareholder Ire Amidst Plummeting Stock and Lawsuit Over 'Inflated Guidance'

Business Upturn

time19 minutes ago

  • Business Upturn

Centene Corporation (CNC) Faces Shareholder Ire Amidst Plummeting Stock and Lawsuit Over 'Inflated Guidance'

SAN FRANCISCO, Aug. 01, 2025 (GLOBE NEWSWIRE) — Before the markets opened on July 25, 2025, investors in Centene Corporation (NYSE: CNC) saw the price of their shares decline about 10% in pre-market trading after the company reported disastrous Q2 2025 financial results. The company, a prominent provider of government-sponsored and commercial healthcare services, finds itself embroiled in a class action lawsuit following a dramatic plunge in its stock price. The suit, Lunstrum v. Centene Corporation, No. 25-cv-05659 (S.D.N.Y.), seeks to represent investors who purchased or acquired Centene securities between December 12, 2024, and June 30, 2025, alleging violations of the Securities Exchange Act of 1934. National shareholders rights firm Hagens Berman continues to investigate the securities law claims and urges Centene investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Class Period: Dec. 12, 2024 – June 30, 2025 Lead Plaintiff Deadline: Sept. 8, 2025 Visit: Contact the Firm Now: [email protected] 844-916-0895 Centene Q2 2025 Financial Results On July 25, 2025, Centene reported a GAAP diluted loss per share of -$0.51 'driven primarily by a reduction in the Company's net 2025 Marketplace risk adjustment revenue transfer estimate.' The Centene Securities Class Action Centene Corporation and its top executives are facing a class-action lawsuit accusing them of portraying an overly optimistic view of the company's financial health and future prospects, misleading investors about its enrollment and market conditions. According to the complaint, during the alleged Class Period, Centene's leadership gave the impression that it had solid, reliable information about projected revenue growth while touting strong enrollment rates and low morbidity levels among its members. For months, Centene's public statements painted a picture of expanding market share and a robust business, particularly focused on serving underinsured and uninsured populations. Yet, the lawsuit alleges that these upbeat reports were disconnected from reality. A preliminary analysis covering more than two-thirds of Centene's Marketplace share reportedly showed lower-than-expected enrollment alongside higher aggregate morbidity rates. This disparity between official statements and internal data forms the core grievance of shareholders. The situation reached a critical point on July 1, 2025, when Centene abruptly withdrew its 2025 financial guidance. The company cited a thorough review of Marketplace data from independent actuarial firm Wakely, revealing that market growth across Centene's 22 Health Insurance Marketplace states was 'lower than expected,' with morbidity levels significantly exceeding and 'materially inconsistent with' the company's earlier assumptions for risk adjustment revenue transfer used in its 2025 guidance. This unexpected revision led to the elimination of Centene's guidance, sending its stock tumbling more than 40 percent and wiping out billions in shareholder value overnight. The lawsuit contends that investors were misled by a narrative of sustained growth and healthy enrollment that, in truth, did not reflect the company's operational realities. 'The allegations, if proven true, suggest a pattern of where Centene's public optimism didn't align with the internal metrics, ultimately leaving investors holding the bag,' stated Reed Kathrein, a partner at Hagens Berman. If you invested in Centene and have substantial losses, or have knowledge that may assist the firm's investigation, submit your losses now » If you'd like more information and answers to frequently asked questions about the Centene investigation, read more » Whistleblowers: Persons with non-public information regarding Centene should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected]. About Hagens Berman Hagens Berman is a global plaintiffs' rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman's team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at Follow the firm for updates and news at @ClassActionLaw. Contact: Reed Kathrein, 844-916-0895 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store